Variation in the cost of managing actinic keratosis

Joslyn S. Kirby, Tanner Gregory, Guodong Liu, Douglas L. Leslie, Jeffrey J. Miller

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

IMPORTANCE Actinic keratosis (AK), a skin growth induced by ultraviolet light exposure, requires chronic management because a small proportion can progress into squamous cell skin cancer. Spending for AK management was more than $1 billion in 2004. Investigating geographic variation in AK spending presents an opportunity to decrease waste or recoup excess spending. OBJECTIVE To evaluate geographic variation in health care cost for management of AKs and the association with patient-related and health-related factors. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort studywas performed using data from the MarketScan medical claims database of 488 324 continuously enrolled members with 2 or more claims for AK. Data from January 1, 2008, to December 31, 2012, was used. MAIN OUTCOMES AND MEASURES Annual costs of carewere calculated for outpatient visits, AK destruction, and medications for AKs, and the total of these components. Costs were adjusted for inflation to 2014 US dollars. To display cost variation, we calculated the ratio of mean cost in the highest quintile (Q5) relative to the mean in the lowest quintile (Q1), or the Q5:Q1 ratio; Q5:Q1 ratios were adjusted based on age, sex, history of nonmelanoma skin cancer, US geographic region, and population density (metropolitan statistical area). RESULTS Overall, data from 488 324 continuously enrolled members (mean [SD] age, 53.1 [7.5] years; 243 662 women) with 2 or more claims for AK were included. Overall, patients had 1 085 985 claims related to AK, and dermatologists accounted for 71.0% of claims. The 2-year total cost was $111.5 million, with $52.4 million in 2011 and $59.1 million in 2012. The unadjusted Q5:Q1 ratios for total annual cost per patient ranged from 9.49 to 15.10. Adjusted ratios ranged from 1.72 to 1.80. CONCLUSIONS AND RELEVANCE There is variation in AK management cost within and between regions. This is not fully explained by differences in patient characteristics such as age, sex, or comorbidities. The annual cost for 10 common conditions from Medicare had lower Q5:Q1 ratios that ranged from 1.33 (joint degeneration of back/neck) to 1.69 (chronic sinusitis) when compared with 1.72 to 1.80 for AKs. This suggests an opportunity to investigate and improve the value of health care delivery in the management of AKs.

Original languageEnglish (US)
Pages (from-to)265-269
Number of pages5
JournalJAMA Dermatology
Volume153
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Actinic Keratosis
Costs and Cost Analysis
Skin Neoplasms
Squamous Cell Neoplasms
Sinusitis
Economic Inflation
Ultraviolet Rays
Medicare
Population Density
Health Care Costs
Comorbidity
Outpatients
Neck
Joints
Databases
Delivery of Health Care
Skin
Health

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

@article{94737a0fd6fe4158aa336b769a64e658,
title = "Variation in the cost of managing actinic keratosis",
abstract = "IMPORTANCE Actinic keratosis (AK), a skin growth induced by ultraviolet light exposure, requires chronic management because a small proportion can progress into squamous cell skin cancer. Spending for AK management was more than $1 billion in 2004. Investigating geographic variation in AK spending presents an opportunity to decrease waste or recoup excess spending. OBJECTIVE To evaluate geographic variation in health care cost for management of AKs and the association with patient-related and health-related factors. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort studywas performed using data from the MarketScan medical claims database of 488 324 continuously enrolled members with 2 or more claims for AK. Data from January 1, 2008, to December 31, 2012, was used. MAIN OUTCOMES AND MEASURES Annual costs of carewere calculated for outpatient visits, AK destruction, and medications for AKs, and the total of these components. Costs were adjusted for inflation to 2014 US dollars. To display cost variation, we calculated the ratio of mean cost in the highest quintile (Q5) relative to the mean in the lowest quintile (Q1), or the Q5:Q1 ratio; Q5:Q1 ratios were adjusted based on age, sex, history of nonmelanoma skin cancer, US geographic region, and population density (metropolitan statistical area). RESULTS Overall, data from 488 324 continuously enrolled members (mean [SD] age, 53.1 [7.5] years; 243 662 women) with 2 or more claims for AK were included. Overall, patients had 1 085 985 claims related to AK, and dermatologists accounted for 71.0{\%} of claims. The 2-year total cost was $111.5 million, with $52.4 million in 2011 and $59.1 million in 2012. The unadjusted Q5:Q1 ratios for total annual cost per patient ranged from 9.49 to 15.10. Adjusted ratios ranged from 1.72 to 1.80. CONCLUSIONS AND RELEVANCE There is variation in AK management cost within and between regions. This is not fully explained by differences in patient characteristics such as age, sex, or comorbidities. The annual cost for 10 common conditions from Medicare had lower Q5:Q1 ratios that ranged from 1.33 (joint degeneration of back/neck) to 1.69 (chronic sinusitis) when compared with 1.72 to 1.80 for AKs. This suggests an opportunity to investigate and improve the value of health care delivery in the management of AKs.",
author = "Kirby, {Joslyn S.} and Tanner Gregory and Guodong Liu and Leslie, {Douglas L.} and Miller, {Jeffrey J.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1001/jamadermatol.2016.4733",
language = "English (US)",
volume = "153",
pages = "265--269",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "4",

}

Variation in the cost of managing actinic keratosis. / Kirby, Joslyn S.; Gregory, Tanner; Liu, Guodong; Leslie, Douglas L.; Miller, Jeffrey J.

In: JAMA Dermatology, Vol. 153, No. 4, 01.04.2017, p. 265-269.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Variation in the cost of managing actinic keratosis

AU - Kirby, Joslyn S.

AU - Gregory, Tanner

AU - Liu, Guodong

AU - Leslie, Douglas L.

AU - Miller, Jeffrey J.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - IMPORTANCE Actinic keratosis (AK), a skin growth induced by ultraviolet light exposure, requires chronic management because a small proportion can progress into squamous cell skin cancer. Spending for AK management was more than $1 billion in 2004. Investigating geographic variation in AK spending presents an opportunity to decrease waste or recoup excess spending. OBJECTIVE To evaluate geographic variation in health care cost for management of AKs and the association with patient-related and health-related factors. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort studywas performed using data from the MarketScan medical claims database of 488 324 continuously enrolled members with 2 or more claims for AK. Data from January 1, 2008, to December 31, 2012, was used. MAIN OUTCOMES AND MEASURES Annual costs of carewere calculated for outpatient visits, AK destruction, and medications for AKs, and the total of these components. Costs were adjusted for inflation to 2014 US dollars. To display cost variation, we calculated the ratio of mean cost in the highest quintile (Q5) relative to the mean in the lowest quintile (Q1), or the Q5:Q1 ratio; Q5:Q1 ratios were adjusted based on age, sex, history of nonmelanoma skin cancer, US geographic region, and population density (metropolitan statistical area). RESULTS Overall, data from 488 324 continuously enrolled members (mean [SD] age, 53.1 [7.5] years; 243 662 women) with 2 or more claims for AK were included. Overall, patients had 1 085 985 claims related to AK, and dermatologists accounted for 71.0% of claims. The 2-year total cost was $111.5 million, with $52.4 million in 2011 and $59.1 million in 2012. The unadjusted Q5:Q1 ratios for total annual cost per patient ranged from 9.49 to 15.10. Adjusted ratios ranged from 1.72 to 1.80. CONCLUSIONS AND RELEVANCE There is variation in AK management cost within and between regions. This is not fully explained by differences in patient characteristics such as age, sex, or comorbidities. The annual cost for 10 common conditions from Medicare had lower Q5:Q1 ratios that ranged from 1.33 (joint degeneration of back/neck) to 1.69 (chronic sinusitis) when compared with 1.72 to 1.80 for AKs. This suggests an opportunity to investigate and improve the value of health care delivery in the management of AKs.

AB - IMPORTANCE Actinic keratosis (AK), a skin growth induced by ultraviolet light exposure, requires chronic management because a small proportion can progress into squamous cell skin cancer. Spending for AK management was more than $1 billion in 2004. Investigating geographic variation in AK spending presents an opportunity to decrease waste or recoup excess spending. OBJECTIVE To evaluate geographic variation in health care cost for management of AKs and the association with patient-related and health-related factors. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort studywas performed using data from the MarketScan medical claims database of 488 324 continuously enrolled members with 2 or more claims for AK. Data from January 1, 2008, to December 31, 2012, was used. MAIN OUTCOMES AND MEASURES Annual costs of carewere calculated for outpatient visits, AK destruction, and medications for AKs, and the total of these components. Costs were adjusted for inflation to 2014 US dollars. To display cost variation, we calculated the ratio of mean cost in the highest quintile (Q5) relative to the mean in the lowest quintile (Q1), or the Q5:Q1 ratio; Q5:Q1 ratios were adjusted based on age, sex, history of nonmelanoma skin cancer, US geographic region, and population density (metropolitan statistical area). RESULTS Overall, data from 488 324 continuously enrolled members (mean [SD] age, 53.1 [7.5] years; 243 662 women) with 2 or more claims for AK were included. Overall, patients had 1 085 985 claims related to AK, and dermatologists accounted for 71.0% of claims. The 2-year total cost was $111.5 million, with $52.4 million in 2011 and $59.1 million in 2012. The unadjusted Q5:Q1 ratios for total annual cost per patient ranged from 9.49 to 15.10. Adjusted ratios ranged from 1.72 to 1.80. CONCLUSIONS AND RELEVANCE There is variation in AK management cost within and between regions. This is not fully explained by differences in patient characteristics such as age, sex, or comorbidities. The annual cost for 10 common conditions from Medicare had lower Q5:Q1 ratios that ranged from 1.33 (joint degeneration of back/neck) to 1.69 (chronic sinusitis) when compared with 1.72 to 1.80 for AKs. This suggests an opportunity to investigate and improve the value of health care delivery in the management of AKs.

UR - http://www.scopus.com/inward/record.url?scp=85017654318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017654318&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2016.4733

DO - 10.1001/jamadermatol.2016.4733

M3 - Article

C2 - 28249074

AN - SCOPUS:85017654318

VL - 153

SP - 265

EP - 269

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 4

ER -